Spruce Biosciences, Inc. (SPRB)
| Market Cap | 151.68M +5,791.7% |
| Revenue (ttm) | n/a |
| Net Income | -37.19M |
| EPS | -38.62 |
| Shares Out | 2.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,348 |
| Open | 51.84 |
| Previous Close | 52.77 |
| Day's Range | 51.78 - 55.35 |
| 52-Week Range | 4.77 - 240.00 |
| Beta | 3.20 |
| Analysts | Strong Buy |
| Price Target | 149.71 (+171.66%) |
| Earnings Date | Aug 13, 2026 |
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for SPRB stock is "Strong Buy." The 12-month stock price target is $149.71, which is an increase of 171.66% from the latest price.
News
Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs
Spruce Biosciences (SPRB) announced the appointment of Agnieszka “AJ” Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs. Most recently, Dr. Jurecka has served as Chief Medical Officer to a...
Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences initiated with a Buy at Guggenheim
Guggenheim analyst Debjit Chattopadhyay initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $123 price target The company expects a biologics license application submission for its l...
Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance
Spruce Biosciences (SPRB) announced the appointments of Eric Jordan as Vice President, Marketing and Tina Gullotta, CPA, as Vice President, Finance and Corporate Controller. Most recently, Jordan serv...
Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences initiated with a Buy at JonesResearch
JonesResearch analyst Catherine Novack initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $135 price target The firm says its valuation of the shares is based on Spruce’s…
Spruce says long-term TA-ERT data presented at MPS Symposium
Spruce Biosciences (SPRB) announced that data demonstrating the long-term benefit of tralesinidase alfa enzyme replacement therapy in patients with Sanfilippo Syndrome Type B were presented at the 18t...
Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Tralesinidase alfa, an enzyme therapy for MPS IIIB, has shown strong biomarker and clinical benefits, with FDA Breakthrough designation and a confirmatory trial underway. Approval is targeted for mid-next year, supported by robust financials and commercial preparations.
Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Spruce Biosciences (SPRB) to $150 from $200 and keeps a Neutral rating on the shares. The firm cites dilution from a recent…
Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Participate in Upcoming Conferences in June
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Transcript: AGM 2026
The meeting confirmed quorum, elected three directors, and approved all proposals, including auditor ratification and annual say-on-pay votes. Management addressed financing, manufacturing, and clinical trial plans, with key milestones aligned with FDA guidance.
Spruce Biosciences price target lowered to $150 from $170 at Citizens
Citizens lowered the firm’s price target on Spruce Biosciences (SPRB) to $150 from $170 and keeps an Outperform rating on the shares. Spruce remains on track to submit its TA-ERT…
Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)
“We are very pleased with the meaningful progress we continue to make in advancing TA-ERT toward our planned biologics license application submission in the fourth quarter of 2026. This would…
Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Earnings release: Q1 2026
Spruce Biosciences released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Spruce Biosciences Quarterly report: Q1 2026
Spruce Biosciences has published its Q1 2026 quarterly earnings report on May 13, 2026.
Spruce Biosciences appoints Brian Walls as VP, market access
Spruce Biosciences (SPRB) announced the appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations. Most recently, Walls served as Vice Pr...
Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy
AS previously reported, Craig-Hallum initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $140 price target. The firm notes the company’s TA-ERT is an enzyme replacement therapy for…
Spruce Biosciences initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Albert Lowe initiated coverage of Spruce Biosciences (SPRB) with a Buy rating and $140 price target
Spruce Biosciences 1.15M share Spot Secondary priced at $50.00
Leerink, Guggenheim and Oppenheimer acted as joint book running managers for the offering.
Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (“Spruce Biosciences”) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel the...
Spruce Biosciences down 13% at $60.50 after equity offering announcement
16:48 EDT Spruce Biosciences (SPRB) down 13% at $60.50 after equity offering announcement